Renaissance Capital logo

CureVac Priced, Nasdaq: CVAC

German Phase 1 biotech developing an mRNA vaccine for SARS-CoV-2.

Industry: Health Care

Latest Trade: $86.00 0.00 (0.0%)

First Day Return: +249.4%

Return from IPO: +437.5%

Industry: Health Care

We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a natural approach to optimize mRNA constructs that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Our lead clinical programs are CV8102, which we are evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which we are currently investigating in a Phase 1 clinical trial for potential vaccination against rabies. We are also rapidly advancing our mRNA vaccine program against coronavirus (SARS-CoV-2), for which we initiated a Phase 1 clinical trial in healthy volunteers in June 2020, with results expected in the fourth quarter of 2020.
more less
IPO News for CureVac
more
IPO Data
IPO File Date 07/24/2020
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 13.3
Deal Size ($mm) $213
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/13/2020
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 13.3
Deal Size ($mm) $213
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Tübingen, Germany
Founded 2000
Employees 484
Website www.curevac.com